Seminars in Oncology
Volume 33, Issue 1 , Pages 106-120 , February 2006

Gastrointestinal Toxicity of Chemotherapeutic Agents

  • Edith P. Mitchell

      Affiliations

    • Corresponding Author InformationAddress correspondence to Edith P. Mitchell, MD, Division of Medical Oncology, Thomas Jefferson University, 125 S Ninth St, Sheridan Building, Suite 801, Philadelphia, PA 19107

References 

  1. Schein PS , MacDonald JS , Waters C , et al.   Nutritional complications of cancer and its treatments . Semin Oncol . 1975;2:334–337
  2. Ohnuma T , Holland JF . Nutritional consequences of cancer chemotherapy and immunotherapy . Cancer Res . 1977;37:2395–2406
  3. Deschner E , Lipkin M . Proliferation and differentiation of gastrointestinal cells in relation to therapy . Med Clin North Am . 1971;55:601–612
  4. Lipkin M , Sherlock P , Bell B . Cell proliferation kinetics in the gastrointestinal tract of man .II Cell renewal in the stomach ileum, colon, rectum . Gastroenterology . 1963;45:721–772
  5. Lipkin M . Cell replication in the gastrointestinal tract of man . Gastroenterology . 1965;48:616–662
  6. Lipkin M . Proliferation and differentiation of gastrointestinal cells . Physiol Rev . 1973;53:891
  7. Lenas L , Steinberg SS , Phillips FS . Cytoxic effects of 1-B-D arabino furnosyl-5-fluorocytosine and 1-B-D arabinofuranosylcytosine in proliferating tissues in mice . Cancer Res . 1970;29:1790–1798
  8. Young RC , Goldberg D , Schein PS . Enhanced antitumor effect of cytosine arabinoside given in a schedule dictated by kinetic studies in vivo . Biochem Pharmacol . 1973;22:277–289
  9. Phillips FS , Steinberg SS , Schwartz HS , et al.   Hydroxyurea 1. Acute cell death in proliferating tissues in mice . Cancer Res . 1974;27:61–74
  10. Tricer JS . Morphologic alterations induced by methotrexate in the mucosa of human proximal intestine . Gastroenterology . 1962;43:407–424
  11. Schwartz HS . Actinomycin D effects on ridgeway sarcoma in mice . Cancer Res . 1966;26:1873–1879
  12. Mitchell EP , Glicksman AS , Schein PS . In: Acute and Late Effects of Cancer Therapy and Their Management in Medical Oncology . New York, NY: McGraw-Hill; 1993;p. 345–369
  13. Marran C , Smith DC , Anderson DA , et al.   Incidence of nausea and vomiting with cytotoxic chemotherapy (A prospective randomized trial of antiemetics) . Br Med J . 1979;1:1323
  14. Coates A , Abraham S , Kaye SB , et al.   On the receiving end. Patient perception of the side effect of cancer chemotherapy . Eur J Cancer Clin Oncol . 1983;19:203–208
  15. Lindley C . Perception of chemotherapy side effects (Cancer vs non cancer patients) . Cancer Pract . 1999;7:59–65
  16. Stewart DJ . Nausea and vomiting in cancer patients . In:  Kucharczyk J ,  Stewart DJ ,  Miller AD editor. Nausea and Vomiting (Recent Research and Clinical Advances) . Boca Raton, FL: CRC Press; 1991;p. 177
  17. Borison HL , Wang WC . Physiology and pharmacology of vomiting . Pharmacol Rev . 1953;5:193–230
  18. Borison HL . Area postrema: Chemoreceptors trigger zone for vomiting. Is that all? . Life Sci . 1974;14:1807–1817
  19. Leslie RA . Neuroactive substances in the dorsal vagal complex of the medulla oblongata (Nucleus of the vagus) . Neurochem Int . 1985;7:191–211
  20. Leslie RA , Shah Y , Thejomayan M , et al.   The neuropharmacology of emesis (The role of receptors in neuro modulation of nausea and vomiting) . Can J Physiol Pharmacol . 1990;68:279–288
  21. Ostuka M , Yoshioka K . Neurotransmitter functions of mammalian tachykinins . Physiol Rev . 1993;73:229–309
  22. Andrews PLR , Naylor RJ , Joss RA . Neuropharmacology of emesis and its relevance to antiemetic therapy (Consensus and controversies) . Support Care Cancer . 1998;6:197–203
  23. Fozard JR . Neuronal 5-HT receptors in the periphery . Neuropharmacology . 1984;23:1473–1486
  24. Tyers MB . 5-HT3 receptors . Ann NY Acad Sci . 1990;600:194–202
  25. Cubeddu LX , Hoffman IS , Fuenmayor NT , et al.   Efficacy of ondansetron (GR338032F) and the role of serotonin in cisplatin-induced nausea and vomiting . N Engl J Med . 1990;322:810–816
  26. Gunning SJ , Hagan RM , Tyers MB . Cisplatin induces biochemical and histologic changes in the small intestine of the ferret . Br J Pharmacol . 1987;90:135; (abstr)
  27. Endo T , Minami M , Monami Y , et al.   Emesis-related biochemical and histochemical changes induces by cisplatin in the ferret . J Toxicol Sci . 1990;15:235–244
  28. Carpenter DO . Neural mechanisms of emesis . Can J Physiol Pharmacol . 1990;68:230–236
  29. Hornby PJ . Receptors and transmission in the brain-gut axis. II Excitatory amino acid receptors in the brain-gut axis . Am J Physiolo Gastrointest Liver Physiol . 2001;280:G1055–G1060
  30. Pisters KMW , Kris MG . Treatment related nausea and vomiting . In:  Berger A ,  Partenoy RK ,  Weissman DE editor. Principles and Practice of Supportive Oncology . Philadelphia, PA: Lippincott-Raven; 1998;p. 165–177
  31. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer . Prevention of chemotherapy and radiotherapy-induced emesis (Results of the Perugia Concensus Conference) . Ann Oncol . 1998;9:811–819
  32. Kris MG , Gralla RJ , Clark RA , et al.   Incidence, course and severity of delayed nausea and vomiting following administration of high dose cisplatin . J Clin Oncol . 1985;3:1379–1384
  33. Morrow GB . Prevalence and correlates of anticipatory nausea and vomiting in chemotherapy patients . J Natl Cancer Inst . 1982;68:585–588
  34. Wilcox PM , Fetting JH , Nettersheim KM , et al.   Anticipatory vomiting in women receiving cyclophosphamide, methotrexate and 5-FU (CMF) adjuvant chemotherapy for breast carcinoma . Cancer Treat Rep . 1982;66:1601–1604
  35. Hesketh PJ , Kris MG , Grunberg SM , et al.   Proposal for classifying the acute emetogenicity of cancer chemotherapy . J Clin Oncol . 1997;15:103–109
  36. Hesketh PJ . Defining the emetogenicity of cancer chemotherapy regimens (Relevance to clinical practice) . Oncologist . 1999;4:191–196
  37. Hesketh PJ , Van Bell S , Napro M , et al.   Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptors antagonists . Eur J Cancer . 2003;39:1074–1080
  38. Cocquyt V , Van Belle S , Reinhardt RR , et al.   Comparison of L-758,298 a jerodrug for the selective neurokinin-1 antagonist L-754, 030, with ondansetron for the prevention of cisplatin induced emesis . Eur J Cancer . 2001;37:835–842
  39. Campos D , Periera JR , Reinhardt RR , et al.   Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone . J Clin Oncol . 2001;19:1759–1767
  40. Tavorath R , Hesketh PJ . Drug treatment of chemotherapy-induced delayed emesis . Drugs . 1996;52:639–648
  41. Wilder-Smith DHG , Borgeat A , Chappuis P , et al.   Urinary serotonin metabolic excretion during cisplatin chemotherapy . Cancer . 1993;72:2239–2241
  42. Jones RJ , Muhonen T , Karjalainen UP , et al.   Urinary 5-hydroxyindolacetic acid (5-HIAA) excretion during multiple day high-dose chemotherapy . Eur J Cancer . 1988;34:196
  43. Gralla RJ , Osoba D , Kris MG , et al.   Recommendations for the use of antiemetics (Evidence-based clinical practice guidelines) . J Clin Oncol . 1999;17:2971–2994
  44. Goedhals L , Heron J-F , Kleisbauer J-P , et al.   Control of delayed nausea and vomiting with granisetron plus dexamethasone alone in patients receiving highly emetogenic chemotherapy (A double-blind, placebo-controlled comparative study) . Ann Oncol . 1998;9:661–666
  45. Kris MG , Tyson LB , Gralla RJ , et al.   Extrapyramidal reactions with high-dose metoclopramide . N Engl J Med . 1983;309:403–434
  46. Allen JC , Gralla RJ , Reilly L , et al.   Metoclopramide dose-related toxicity and preliminary antiemetic studies in children receiving chemotherapy . J Clin Oncol . 1985;3:1136–1141
  47. Hesketh PJ , Plagge P , Bryson JC . Single-dose ondansetron for prevention of acute cisplatin-induced emesis (Analysis of efficacy and prognostic factors) . In:  Branch AL ,  Grelot L ,  Miller AD editor. Mechanisms and Control of Emesis . London, UK: INSERM/John Libbey Eurotext; 1992;p. 235–243
  48. D’Acquisto RW , Tyson LB , Gralla RJ , et al.   The influence of chronic high alcohol intake on chemotherapy-induced nausea and vomiting) . Proc Am Soc Clin Oncol . 1986;5:257; (abstr 1006)
  49. Berger AH , Clark-Snow RA . Nausea and vomiting . In:  DeVita VT ,  Hellman S ,  Rosenberg SA editor. Cancer (Principles and Practice of Oncology) . Philadelphia, PA: Lippincott Williams & Wilkins; 2001;p. 2869–2880
  50. In:  Holland JF ,  Frei E editor. Cancer Medicine . (ed 2). Philadelphia. PA: Lea & Febiger; 1982;p. 2332
  51. Jacobsen P , Andrykowski M , Redd W , et al.   Nonpharmacologic factors in the development of posttreatment nausea with adjuvant chemotherapy for breast cancer . Cancer . 1988;61:379
  52. Martin M , Diaz-Rubio E . Emesis during pregnancy (A new prognostic factor in chemotherapy-induced emesis) . Ann Oncol . 1990;1:152
  53. Morrow GR . The effect of a susceptibility to motion sickness on the side effects of cancer chemotherapy . Cancer . 1985;55:2766
  54. Guillem V , Aranda E , Carrato A , et al.   Previous history of emesis during pregnancy and motion sickness as risk factors for chemotherapy-induced emesis . J Clin Oncol . 1999;2280:590a; (abstr)
  55. Grunberg SM , Hansen M , Denson RR , et al.   Incidence of chemotherapy-induced nausea and emesis after modern antiemetics . Cancer . 2004;100:2261–2268
  56. Latreille J , Peter J , Johnston D , et al.   Use of dexamethasone and granisetron in the control of delayed emesis for patients who received highly emetogenic chemotherapy . J Clin Oncol . 1998;16:1174–1178
  57. desWit R , Van den Bergtt S , Burghouts J , et al.   Initial high antiemetic efficiency of granisetron with dexamethasone is not maintained over repeated cycles . Br J Cancer . 1998;77:1487–1491
  58. Koeller JM , Aapro MS , Gralla RJ , et al.   Antiemetic guideline (Creating a more practical treatment approach) . Support Care Cancer . 2002;10:519–522
  59. Multinational Association for Supportive Care in Cancer-Perugia International Cancer Conference VII-Concensus Conference on Antiemetic Therapy. Perugia 2004 antiemetic guidelines (online). http://www.mascc.org
  60. National Comprehensive Cancer Network Clinical Guidelines and Outcomes Data in Oncology. www.nccn.org
  61. Miner WD , Sanger GJ , Turner DH . Evidence that 5-hydroxtryptamines receptors mediate cytotoxic drug and radiation-evoked emesis . Br J Cancer . 1987;56:159–162
  62. Gralla RJ , Itri LM , Pisko SE , et al.   Antiemetic efficacy of high-dose metoclopramide (Randomized trials with placebo and prochlorperazine inpatients with chemotherapy-induced nausea and vomiting) . N Engl J Med . 1981;305:905
  63. Einhorn LH , Nagy C , Werner K , et al.   Ondasetron (A new antiemetic for patients receiving cisplatin chemotherapy) . J Clin Oncol . 1990;8:731–735
  64. Marty M , Pouillart P , Scholl S , et al.   Comparison of the 5-hydroxytryptamine (serotonin) antagonist ondansetron (GR38032F) with high dose metoclopramide in the control of cisplatin-induced emesis . N Engl J Med . 1990;322:816–821
  65. DeMulder PHM , Seynaeve C , Vermorken JB , et al.   Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting . Ann Intern Med . 1990;113:834–840
  66. Hainesworth J , Harvey W , Pendergrass K , et al.   A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy . J Clin Oncol . 1991;9:721–728
  67. Chevallier B . The control of acute cisplatin-induced emesis—A comparative study of granisetron and a combination regimen of high-dose metoclopramide and dexamethasone . Br J Cancer . 1993;68:176–180
  68. Sledge GW , Einhorn L , Nagy C , et al.   Phase III double-blind comparison of intravenous ondansetron and metoclopramide as anti-emetic therapy for patients receiving multiple-day cisplatin-based chemotherapy . Cancer . 1992;70:2524–2528
  69. The Granisetron Study Group . The anti-emetic efficacy and safety of granisetron compared with metoclopramide plus dexamethasone in patients receiving fractionated chemotherapy over 5 days . J Cancer Res Clin Oncol . 1993;119:555–559
  70. Chevallier B , Cappelaere P , Splinter T , et al.   A double-blind, multicentre comparison of intravenous dolasetron mesylate and metoclopramide in the prevention of nausea and vomiting in cancer patients receiving high-dose cisplatin chemotherapy . Support Care Cancer . 1997;5:22–30
  71. Warr D , Willan A , Fine S , et al.   Superiority of granisetron to dexamethasone plus prochlorperazine in the prevention of chemotherapy-induced emesis . J Natl Cancer Inst . 1991;83:1169–1173
  72. Bonneterre J , Chavallier B , Metz R , et al.   A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy . J Clin Oncol . 1990;8:1063–1069
  73. Marschner NW , Adler M , Nagel GA , et al.   Double-blind randomized trial of the anti-emetic efficacy and safety of ondamsetron and metoclopramide in advanced breast cancer patients treated with epirubicin and cyclophosphamide . Eur J Cancer . 1991;27:1137–1140
  74. Jones AL , Hill AS , Soukop M , et al.   Comparison of dexamethasone and oondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy . Lancet . 1991;338:483–487
  75. Marty M . A comparative study of the use of granisetron regimen of chlorpromazine plus dexamethasone in the treatment of cytostatic-induced emesis . Eur J Cancer . 1990;26(suppl 1):S28–S32
  76. Kris MG , Gralla RJ , Clark RA , et al.   Dose-ranging evaluation of the serotonin antagonist GRC507/75 (GR38032F) when used as an anti-emetic in patients receiving anticancer chemotherapy . J Clin Oncol . 1988;6:659–662
  77. Grunberg SM , Stevenson LL , Russell CA , et al.   Dose ranging phase I study of the serotonin antagonist GR38032F for prevention of cisplatin-induced nausea and vomiting . J Clin Oncol . 1989;7:1137–1141
  78. Riviere A . Dose finding study of granisetron in patients receiving high-dose cisplatin chemotherapy . Br J Cancer . 1994;69:967–971
  79. Kris MG , Grunberg SM , Gralla RJ , et al.   Dose-ranging evaluation of the serotonin antagonist dolasetron in patients receiving high-dose cisplatin . J Clin Oncol . 1994;12:1045–1049
  80. Eisenberg P , Rubinstein EB , Cohen L . Efficacy safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy (A dose-ranging, clinical study) . Ann Oncol . 2004;15:330–337
  81. Fauser AA , Ducios B , Chemaissam A , et al.   Therapeutic equivalence of single oral dose of dolasetron mesylate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy . Eur J Cancer . 1996;32A:1523–1529
  82. Martoni S , Angelelli B , Guaraldi M , et al.   Granisetron versus ondansetron in the prevention of cisplatinum-induced emesis (An open randomized cross-over study) . Proc Am Soc Clin Oncol . 1994;13:431; (abstr)
  83. Navari R , Gandara D , Hesketh P , et al.   Ondansetron compared with granisetron and ondanstron in the prophylaxis of cisplatin-induced emesis . J Clin Oncol . 1995;13:1242–1248
  84. Ruff P , Paska W , Goedhals L , et al.   Ondansetron compared with granisetron in the prophylaxis pf cisplatin-induced emesis (A multicenter double-blind, randomized, parallel-group study) . Oncology . 1994;41:113–118
  85. Hesketh P , Navari R , Grote T , et al.   Double-blind, randomized comparison of the anti-emetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer . J Clin Oncol . 1996;14:2242–2249
  86. Audhuy B , Cappelaere P , Martin M , et al.   A double-blind, randomized comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesylate and granisetron in patients receiving high dose cisplatin chemotherapy . Eur J Cancer . 1996;32A:807–813
  87. Bonneterre T , Hecquet B . Granisetron (Iv) compared with ondansetron (Iv plus oral) in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy (A cross-over study) . Bull Cancer . 1995;82:1038–1043
  88. Stewart A , McQuade B , Cronje JD , et al.   Ondansetron compared with granisetron in the prophylaxis of cyclophosphamide-induced emesis in outpatients (A multicenter, double-blind, double-dummy, randomized, paraellel-group study) . Oncology . 1995;52:202–210
  89. DelGiglio A , Soares HP , Caparroz C , et al.   Granisetron is equivalent to ondansetron for prophylaxis of chemotherapy induced nausea and vomiting (Results of a meta-analysis of randomized controlled trials) . Cancer . 2000;89:2301–2308
  90. Gralla R , Lichinitserm M , Van der Vegts G . Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy (results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron) . Ann Oncol . 2003;14:1570–1577
  91. Rubenstein EB , et al.   Palonosetron (PALO) compared with ondansetron (OND) or dolasetron (DOL) for prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) (Combined results of two phase III trials) . Proc Am Soc Clin Oncol . 2003;22:729; (abstr 2932)
  92. Aloxi (package insert) . Bloomington, MN: MGI Pharma, Inc; 2004;
  93. Zofran (package insert) . Research Triangle Park, NC: GlaxoSmithKline; 2001;
  94. Anzemet (package insert) . Bridgewater, NJ: Aventis Pharmaceuticals; 2000;
  95. Kytril (package insert) . Inc, Nutley, NJ: Roche Laboratories; 2000;
  96. Wong EHF , Clark R , Leung E , et al.   The interaction of RS 25259-197, a potent and selective antagonist, with 5-HT3 receptors in vitro . Br J Pharmacol . 1995;114:851–859
  97. Miller RC , Galvan M , Gittos MW , et al.   Pharmacological properties of dolasetron, a potent and selective antagonist at 5HT3, receptors . Drug Dev Res . 1993;28:87–93
  98. Aapro MS , Macciochi A . Palonosetron (PALO) is more effective than ondansetron/dolasetron (OND/DOL) in prevention chemotherapy induced nausea and vomiting (CINV) in elderly patients (Combined results from 2 phase III trials) . Proc Am Soc Clin Oncol . 2004;23:737; (abstr)
  99. Gralla RJ , Itri LM , Pisko SE , et al.   Antiemetic efficacy of high-dose metoclopramide (Randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting) . N Engl J Med . 1981;305:905–909
  100. Basurto C , Roila F , Tonato M , et al.   Antiemetic activity of high dose metoclopramide combined with methylprednisolone versus metoclopramide alone in dacarbazine-treated cancer patients. A randomized double blind study of Italian Oncology Group for Clinical Research . Am J Clin Oncol . 1989;12:235
  101. Kris MG , Gralla RJ , Clark RA , et al.   Antiemetic control and prevention of side effects of anticancer therapy with lorazepam or diphenhydramine when used in conjunction with metoclopramide plus dexamethasone. A double blind, randomized trial . Cancer . 1987;69:1353
  102. Kris MG , Gralla RJ , Tyson LB , et al.   Improved control of cisplatin induced emesis with high dose metoclopramide and with combinations of metoclopramide, dexamethasone and dipyhenhydramine. Results of consecutive trials in 255 patients . Cancer . 1985;55:527
  103. Roila F , De Angelis V , Cognetti F , et al.   Ondansetron vs. granisetron, both combined with dexamethasone in the prevention of cisplatin induced emesis . Proc Am Soc Clin Oncol . 1995;14:523; (abstr)
  104. DeMulder PHM , Seynaeve C , Vermorker JB , et al.   Ondasetron compared with high dose metoclopramide in prophylaxis of acute and delayed cisplatin induced nausea and vomiting. A multicenter, randomized double blind, crossover study . Ann Intern Med . 1990;113:834
  105. Kris MG , Gralla RJ , Tyson LB , et al.   Controlling delayed vomiting (A double blind randomized trial comparing placebo, dexamethasone alone and metoclopramide plus dexamethasone in patients receiving cisplatin) . J Clin Oncol . 1989;7:108
  106. Kris MG , Gralla RJ , Tyson LB , et al.   Improved control of cisplatin induced emesis with high dose metoclopramide and with combinations of metoclopramide, dexamethasone, and diphenhydramine. Results of consecutive trials in 255 patients . Cancer . 1985;55:527
  107. Beck TM , Hesketh PJ , Madajewicz S , et al.   Stratified, randomized, double blind comoparison of intravenous ondansetron administered as a multiple dose regimen versus two single dose regimens in the prevention of cisplatin-induced nausea and vomiting . J Clin Oncol . 1992;10:1969–1975
  108. Seynaeve C , Schuller J , Buser J , et al.   Comparison of the antiemetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin induced emesis. A multicentre, double blind, randomized parallel group study . Br J Cancer . 1992;66:192–197
  109. Marty M , D’Allens H . A single daily dose of ondansetron is as effective as a continuous infusion in the prevention of cisplatin-induced nausea and vomiting . Ann Oncol . 1990;1(suppl 1):112–120
  110. Chiarra S , Campora E , Lionetto R , et al.   Methylprednisolone for the control of CMF-induced emesis . Am J Clin Oncol . 1987;10:264–267
  111. Roila F , Tonato M , Basurto C , et al.   Double-blind controlled trial of the antiemetic efficacy and toxicity of methylprednisolone (MP), metoclopramide (MTC) and domperidone (DMP) in breast cancer patients treated with I.V. CMF . Eur J Cancer Clin Oncol . 1987;23:615–617 1987
  112. Zaglama NE , Rosenblum SL , Sartiano GP , et al.   Single, high-dose intravenous dexamethasone as an antiemetic in cancer chemotherapy . Oncology . 1986;43:27–32
  113. Cassileth PA , Lusk EJ , Torri S , et al.   Antiemetic efficacy of high-dose dexamethasone in induction therapy in acute nonlymphocytic leukemia . Ann Intern Med . 1984;100:701–702
  114. Rittenberg CN , Gralla REJ , Lettow LA , et al.   New approaches in preventing delayed emesis (altering the time of regimen initiation and use of combination therapy in a 1009 patient trial) . Proc Am Soc Clin Oncol . 1995;14:526; (abstr)
  115. Roila F , Tonato M , Cognetti F , et al.   Prevention of cisplatin-induced emesis (a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone) . J Clin Oncol . 1991;9:675
  116. Kris MG , Gralla RJ , Tyson LB , et al.   Controlling delayed vomiting (A double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone n patients receiving cisplatin) . J Clin Oncol . 1989;7:108
  117. Navari R , Gandara D , Hesketh P , et al.   Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis . J Clin Oncol . 1995;13:1242
  118. Kris MG , Grunberg SM , Gralla RJ , et al.   Dose-ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving high dose cisplatin . J Clin Oncol . 1994;12:1045
  119. Kris MG , Gralla RJ , Clark RA , et al.   Phase II trials of the serotonin antagonist GR38032F for the control of vomiting caused by cisplatin . J Natl Cancer Inst . 1989;81:42
  120. Jesketh PJ , Murphy WK , Lester RP , et al.   Gr38032F (A novel compound effective in the prevention of acute cisplatin-induced emesis) . J Clin Oncol . 1989;7:700
  121. Hainsworth J , Harvey W , Pendergrass K , et al.   A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy . J Clin Oncol . 1991;9:721
  122. Kaplan HG , Jofthagen C . Use of granisetron to prevent platinol induced nausea and vomiting . Proc Am Soc Clin Oncol . 1991;10:339; (abstr 1202)
  123. Schrnoll HJ . The role of ondansetron in the treatment of emesis induced by non-cisplatin-containing chemotherapy regimes . Eur J Cancer . 1991;25(suppl 1):555
  124. Roila F , DeAngelis V , Cognetti F , et al.   Ondansetron vs. granisetron, both combined with dexamethasone in the prevention of cisplatin-induced emesis . Proc Am Soc Clin Oncol . 1995;14:523; (abstr)
  125. Kris MG , Gralla RJ , Clark RA , et al.   Dose ranging evaluation of the serotonin antagonist GR-C507/75 (GR38032F) when used as antiemetic in patients receiving cancer chemotherapy . J Clin Oncol . 1988;6:659
  126. The Italian Group for Antiemetic Trials . Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer . N Engl J Med . 1995;332:1
  127. Roila F , DeAngelis V , Cognetti F , et al.   Ondansetron vs. granisetron, both combined with dexamethasone in the prevention of cisplatin-induced emesis . Proc Am Soc Clin Oncol . 1995;14:523; (abstr)
  128. Kris MG , Gralla RJ , Clark RA , et al.   Antiemetic control and prevention of side effects of anticancer therapy with lorazepam or diphenhydramine when used in conjunction with metoclopramide pluse dexamethasone. A double-blind, randomized trial . Cancer . 1987;69:1353
  129. Dilly SG , Friedman C , Yokom K . Contribution of dexamethasone to antiemetic control with granisetron is greatest in patients at high risk of emesis . Proc Am Soc Clin Oncol . 1994;13:436; (abstr)
  130. Devane CL . Substance P (A new era, a new role) . Pharmacology . 2001;21:1061–1069
  131. Hargraves R . Imaging substance preceptors (NK1) in the living human brain using positron emission tomography . J Clin Psychiatry . 2002;63(suppl 11):18–24
  132. Saria A . The tachykenin NK1 receptor in the brain (Pharmacology and putative functions) . Eur J Pharmacol . 1999;375:51–60
  133. Hesketh PJ . Potential roles of the NK1 receptor antagonists in chemotheraphy-induced nausea and vomiting . Support Care Cancer . 2001;9:350–354
  134. Tappersall FD , Rycroft W , Francis B , et al.   Tachykenin NK1 receptor antagonists act centrally to inhibit emesis-induced by the chemotherapeutic agent cisplatin in ferrets . Neuropharmacology . 1996;35:1121–1129
  135. Cocqreyt V , VanBelle S , Reinhardt RR , et al.   Comparison of L-758, 298, a prodrug for the selective neurokinin-1 antagonist, L-574,030, with ondansetron for the prevention of cisplatin-induced emesis . Eur J Cancer . 2001;37:835–842
  136. Hesketh PJ , VanBelle S , Aapro MS , et al.   Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists . Eur J Cancer . 2003;39:1074–1080
  137. Navari RM , Reinhardt RR , Gralla RJ , et al.   Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist . N Engl J Med . 1999;340:190–195
  138. Campos D , Pereira J , Reinhardt R , et al.   MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone . J Clin Oncol . 2001;19:1759–1767
  139. Kris MG , Radford JE , Pizzo BA , et al.   Use of an NK-1 receptor antagonist to prevent delayed emesis after cisplatin . J Natl Cancer Inst . 1997;89:817–818
  140. Hesketh PJ , Gralla RJ , Webb RT , et al.   Randomized phase II study of the neurokinin-1-receptor antagonist CJ-11, 974 in the control of cisplatin-induced emesis . J Clin Oncol . 1999;17:338–343
  141. VanBelle S , Lichinitser MR , Navari RM , et al.   Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869. A randomized controlled trial . Cancer . 2002;94:3032–3041
  142. Acute Leukemia Group B . Acute lymphocytic leukemia in children . JAMA . 1969;207:923–928
  143. Lamb EJ , Morton DG , Byron RC . Methotrexate therapy of choriocarcinoma and allied tumors . Am J Obstet Gynecol . 1964;90:317–327
  144. Djerassi I , Farber S , Abir E , et al.   Continuous infusion of methotrexate in children with acute leukemia . Cancer . 1967;20:233–242
  145. Bleyer WA . The clinical pharmacology of methotrexate . Cancer . 1978;41:36–51
  146. Dritschilo A , Prio AJ . Clinical combinations of radiation and drugs in the management of tumors . In:  Sokol GH ,  Maickel RP editor. Radiation-Drug Interactions in the Treatment of Cancer . New York, NY: Wiley; 1980;p. 180–186
  147. Young RC , Chabner BA . An in vivo method for determining differential effects of chemotherapy on targets tissues in animals and man. Correlation with plasma pharmacokinetics . J Clin Invest . 1973;52:92; (abstr)
  148. Chabner BA , Myers CE , Oliverio VR . Clinical pharmacology or anticancer drugs . Semin Oncol . 1977;2:165–191
  149. Chabner BA , Young RC . Threshold methotrexate concentration for in vivo inhibition of DNA synthesis in normal and tumorous target tissues . J Clin Invest . 1973;52:1804–1811
  150. Stroller RG , Jacobs SA , Drake JC , et al.   Pharmacokinetics of high-dose methotrexate (NSC-740) . Cancer Chemother Rep . 1975;6:19–24
  151. Huffman DH , Wan SH , Azarnoff DL , et al.   Pharmacokinetics of high-dose methotrexate (NSC 740) . Clin Pharmacol Ther . 1973;14:572–576
  152. Stroller RG , Hande KR , Jacobs SA , et al.   Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity . N Engl J Med . 1977;297:630–634
  153. Chabner BA , Johns DG , Bertino JR . Enzymatic cleavage of methotrexate provides a method for prevention of drug toxicity . Nature . 1972;239:395–397
  154. Isacoff WH , Townsend CM , Eilber FR , et al.   High dose methotrexate therapy of solid tumors (Observations relating to clinical toxicity) . Med Pediatr Oncol . 1976;2:319–325
  155. Jacobs WA . Methotrexate (Clinical pharmacology; current status and therapeutic guidelines) . Cancer Treat Rev . 1977;4:87–101
  156. Leavitt M , Masher MS , DeCanti RC . Improved therapeutic index of methotrexate with “leucovorin rescue” . Cancer Res . 1973;33:1729–1734
  157. Jacobs SA , Bleyer WA , Chabner BA , et al.   Altered plasma pharmacokinetics of methotrexate administered intrathecally . Lancet . 1975;1:455–456
  158. Wan SH , Huffman DH , Azarnoff DL , et al.   Effects of route of administration and effusions on methotrexate pharmacokinetics . Cancer Res . 1974;34:3487–3491
  159. Ansfield FS , Ramirez G . The clinical results of 5-flourouracil intrahepatic areterial infusion in 528 patients with metastic cancer to the liver . In:  Ariel IM editors. Progress in Clinical Cancer . vol 7: New York, NY: Grune & Stratton; 1978;p. 201–206
  160. Sherlock P . Acute gastritis from regional infusion of an antimetabolite . Bull Gastrointest Endosc . 1963;9:16–20
  161. Innocenti M . Efficacy of Gelclair in reducing pain in palliative care patients with oral lesion (Preliminary findings from an open pilot study) . J Pain Sympt Management . 2003;24:456–457
  162. Rubin JS , Osada H , Finch PW , et al.   Purification and characterization of newly identified growth factor specific for epithelial cells . Proc Natl Acad Sci U S A . 1989;86:802–806
  163. Rubin JS , Botarro DP , Chedid M , et al.   Keratinocyte growth factor . Cell Biol Int . 1995;19:399–411
  164. Finch PW , Rubin JS , Miki T , et al.   Human KGF is FGF-related with properties of a paracrine effector of epithelial growth . Science . 1989;245:752–755
  165. Spielberger R , Stiff P , Bensinger W , et al.   Palifermin for oral mucositis after intensive therapy for hematologic cancers . N Engl Med . 2004;351:2590–2598
  166. Wurth MA , Musacchila XJ . Mechlorethamine effects on intestinal absorption in vitro and on cell proliferation . Am J Physiol . 1973;225:73–80
  167. Sobhon R , Wanichanon C , Stretarugsa P . Morphological changes induced by cyclophosphamide in crypt epithelium of the small intestine in mice . Am J Anat . 1977;149:563–584
  168. Shaw MT , Spector MH , Ladman AJ . Effects of cancer, radiotherapy and cytotoxic drugs on intestinal structure and function . Cancer Treat Rev . 1979;6:141–151
  169. Muggia AL , Wagman E , Milles SS , et al.   Response of the gastrointestinal tract of the mouse to 5-fluorouracil . Am J Pathol . 1963;42:407–414
  170. Roche AC , Bognel JC , Boguel C , et al.   Correlation between the histological changes and glucose intestine absorption following a single dose of 5-fluorouracil . Digestion . 1970;3:195–212
  171. Ecknauer R , Lohrs U . The effect of a single dose of cyclophosphamide on the jejunum of specified pathogen fall and germ free rats . Digestion . 1976;14:269–280
  172. Small MD , Cavanaugh RL , Gottlieb L , et al.   The effect of aminoprotein on the absorption of xylose from the rat small intestine . Am J Dig Dis . 1959;4:700–705
  173. Venho VMK . Effect of methotrexate on drug adsorption from rat small intestine in situ and in vitro . Acta Pharmacol Toxicol . 1966;38:450–464
  174. Hartwich G , Domschke W , Matzkies F . Disaccharidases of the intestinal mucosa of the rat with vincristine sulfate and ifosfamide . Arzreisn Forsch . 1976;26:350–352
  175. Ohnuma T , Holland JF , Nagel G , et al.   Effects of L-asparaginase in acute myelocytic leukemia . JAMA . 1969;210:1919–1921
  176. Ohnuma T , Holland JF , Frieman A , et al.   Biochemical and pharmacological studies with asparaginase in man . Cancer Res . 1970;30:2297–2305
  177. Craft SW , Kay HEM , Lawson DN , et al.   Methotrexate-induced malabsorption in children with acute lymphoblastic leukemia . Br Med J . 1977;2:1511–1512
  178. Slavin RE , Dias MA , Sarol R . Cytosine arabinoside induced gastrointestinal toxic alterations in sequential chemotherapeutic protocols . Cancer . 1978;42:1747–1759
  179. Smith FP , Kisner D , Widerlite L , et al.   Chemotherapeutic alterations of small intestinal morphology and function (A progress report) . Clin Gastroenterol . 1979;1:203–207
  180. Smith FP , Kisner D , Schein PL . Nutrition and cancer (Prospects for clinical research) . Nutr Cancer . 1980;2:34–39
  181. Dymock IW , Mackay N , Miller V , et al.   The effect of cancer on small intestinal function . Br J Cancer . 1967;21:505–511
  182. Weiss H , Walker M , Wiernik P . Neurotoxicity of common used antineoplastic agents . N Engl J Med . 1974;291:75–81 127-133
  183. Rosenthal S , Kaufman S . Vincristine neurotoxicity . Ann Intern Med . 1975;80:733–737
  184. Holland JF , Scharlau C , Gailani S , et al.   Vincristine treatment of advances cancer (a cooperative study of 392 cases) . Cancer Res . 1973;33:1258–1264
  185. Sandler SG , Tobin W , Henderson ES . Vincristine induced neuropathy (A clinical study of fifty leukemia patients) . Neurology (Minn) . 1969;19:367–374
  186. Sherlock P . Effect of cancer treatment on nutrition and gastrointestinal function . Clin Bull . 1979;9:136–145
  187. Killen J , Mitchell EP , Woolley PV , et al.   Phase II studies of methylglyoxal-bis-guanylhydrazone . Cancer . 1982;50:1258–1261
  188. Benson AB , Ajani JA , Catalano RB , et al.   Recommended guidelines for the treatment of cancer treatment-induced diarrhea . J Clin Oncol . 2004;22:2918–2926
  189. Eras P , Goldstein MJ , Sherlock P . Candida infections of the gastrointestinal tract . Medicine . 1972;51:367–379
  190. Bodey GPL . Fungal infections complicating acute leukemia . J Chronic Dis . 1966;19:667–687
  191. Kaufman SA , Scheff S , Levine G . Esophageal moniliasis . Radiology . 1960;75:726–732
  192. Lewicki AM , Moore JP . Esophageal moniliasis (A review of common and less frequent characteristics) . Am J Roentgenol Radium Ther Nucl Med . 1975;125:218–225
  193. Svejgaard E . Miconazole in the treatment of candidiasis of the digestive tract . Acta Dermatovnor . 1976;56:303–306
  194. Medoff G , Dismukes WE , Meade RH , et al.   A new therapeutic approach to candida infection . Arch Intern Med . 1972;130:241–243
  195. Ehrlich AN , Stalder G , Gellew W , et al.   The gastrointestinal manifestations of malignant lymphoma . Gastroenterology . 1968;54:1115–1121
  196. Hartman WH , Sherlock P . Gastroduodenal metastases from carcinoma of the breast (an adrenal steroid-induced phenomenon) . Cancer . 1961;14:426–431
  197. Donaldson SS , Castro JR , Wilbur JR , et al.   Rhabdomyosarcoma of head and neck in children (Combination treatment by surgery, irradiation and chemotherapy) . Cancer . 1973;31:26–35
  198. Donaldson SS , Jundt S , Ricour C , et al.   Radiation enteritis in children (A retrospective review, clinicopathologic correlation and dietary management) . Cancer . 1975;35:1167–1178
  199. Donaldson SS , Lenon RA . Alteration of nutritional status (The impact of chemotherapy and radiation therapy) . Cancer . 1979;43:2036–2052
  200. Donaldson SS . Nutritional consequences of radiotherapy . Cancer Res . 1977;37:2407–2413
  201. Cassady JR , Tefft U , Filler RM , et al.   Consideration in the radiation therapy of Wilms’ tumor . Cancer . 1973;32:598–608
  202. Bagshaw MA , Doggett RLS . A clinical study of radiosensitization . In:  Front D editors. Radiation Therapy Oncology . vol 4: New York, NY: Skarger; 1969;p. 164–173
  203. Von Essen CF , Kligerman MM , Calabresi PL . Radiation and 5-flourouracil. A controlled clinical study . Radiology . 1963;81:1018–1027
  204. Phillips TL , Wharam MD , Margolis LW . Modification of radiation injury to normal tissues by chemotherapeutic agents . Cancer . 1975;35:1678–1684
  205. Lerner H , Beckloff M , Goodwin C . Concomitant hydroxyurea and radiotherapy in the management of 60 patients with head and neck cancer . Am Surg . 1969;35:525–534
  206. Phillips FS , Sternberg SS , Schwartz HS , et al.   Hydroxyurea 1. Acute cell death in proliferating tissues in mice . Cancer Res . 1967;27:61–74
  207. Hall T , Diderick M , Chalmers T , et al.   A clinical pharmacologic study of chemotherapy and x-ray therapy in lung cancer . Am J Med . 1967;43:186–193
  208. Concannon JP , Dalbow MH , Hageman RF , et al.   Radiation and actinomycin D mortality studies in C’57 BL/6 mice . Cancer . 1973;32:553–561
  209. Concannon JP , Summers RE , King J , et al.   Enhancement of x-ray effect on the small intestinal epithelium of dogs by actinomycin . Am J Roentgenol . 1969;105:126–136
  210. Byfield JE , Watring WG , Lemkin SR , et al.   Adriamycin (A useful adjuvant drug for combination with radiation therapy) . Proc Am Assoc Cancer Res . 1975;16:253; (abstr)
  211. Mayer EG , Paulter C , Aristzapal SL . Complications of irradiation related to apparent drug potentiation by adriamycin . Int J Radiat Oncol Biol Phys . 1976;1:1179–1188
  212. Greco FA , Brereton HD , Kent H , et al.   Adriamycin and enhanced radiation reaction in normal esophagus and skin . Ann Intern Med . 1976;85:294–298
  213. Brereton HD , Kent CH , Johnson REL . Chemotherapy and radiation therapy for small cell cancer of the lung (A remedy for past therapeutic failure) . In:  Muggia F ,  Rozencweig M editor. Lung Cancer (Progress in Therapeutic Research) . New York, NY: Raven; 1979;p. 579–586
  214. Moertel CG , Childs DS , Reitemeir RJ , et al.   Combined 5-flourouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer . Lancet . 1969;2:865–867
  215. Landgren RC , Hussey DH , Barkley HT , et al.   Split-course irradiation plus hydroxyurea in inoperable bronchogenic carcinoma. A randomized study of 53 patients . Cancer . 1974;34:1598–1601
  216. Landgren RC , Hussy DH , Samuels M , et al.   A randomized study comparing irradiation alone to irradiation plus procarbazine in inoperable bronchogenic carcinoma . Radiology . 1973;108:403–406
  217. Coy P . A randomized study of irradiation and vinblastine in lung cancer . Cancer . 1970;26:803–807
  218. Donaldson SS , Glick JM , Wilbur SR . Adriamycin activating a recall phenomenon after radiation therapy . Ann Intern Med . 1974;81:407–408
  219. Watring WG , Byfield JE , Lagasse LD , et al.   Combination of Adriamycin and radiation therapy in gynecologic cancers . Gynecol Oncol . 1974;2:518–526
  220. Fox BW , Lagtha LG . Radiation damage and repair phenomenon . Br Med Bull . 1973;29:16–22
  221. Dritschilo A , Piro AJ , Bell JA . Interaction between radiation and drug damage in mammalian cells. III: The effect of Adriamycin and actinomycin D on the repair of potentially lethal radiation damage . Int J Radiat Biol Phys . 1979;35:549–560
  222. Phillips TL , Fu K . Quantification of combined radiation therapy and chemotherapy effects on normal tissue . Cancer . 1976;37:1186–1200
  223. Sonchon EA , Copeland EM , Watson P , et al.   Intravenous hyperalimentation as an adjunct to cancer chemotherapy with fluorouracil . Surg Res . 1975;18:451–454
  224. Copeland EM , MacFayden BV , Dudrick SJ . Intravenous hyperalimentation in cancer patients . J Surg Res . 1974;16:241–247
  225. Copeland EM , MacFayden BV , MacComb WS , et al.   Intravenous hyperalimentation with head and neck cancer . Cancer . 1975;35:606–611
  226. Copeland EM , MacFayden BV , Lanzotti V , et al.   Intravenous hyperalimentation as an adjunct to cancer chemotherapy . Am J Surg . 1975;129:167–173
  227. Lanzo HIV , Copeland EM , George S . Cancer chemotherapeutic response and intravenous hyperalimentation . Cancer Treat Rep . 1975;59:437–439
  228. Copeland EM , MacFayden BV , MacCombs WS , et al.   Intravenous hyperalimentation as an adjunct to cancer treatment in the adult . Cancer Res . 1977;37:2451–2456
  229. Filler RM , Jaffe N , Cassady JR , et al.   Parenteral nutritional support in children with cancer . Cancer . 1977;39:2665–2669
  230. Schwartz G , Green H , Bendon M , et al.   Combined parenteral hyperalimentation and chemotherapy in the treatment of disseminated solid tumors . Am J Surg . 1977;121:169–173
  231. Bounous G , Gentiles JM , Hugon J . Elemental diet in the intestinal lesion produced by 5-fluorouracil in man . Can J Surg . 1971;14:312–324

PII: S0093-7754(05)00494-X

doi: 10.1053/j.seminoncol.2005.12.001

Seminars in Oncology
Volume 33, Issue 1 , Pages 106-120 , February 2006

Article Tools

* Image Usage & Resolution